Production and in vitro characterization of solid dosage form incorporating drug nanoparticles

Drug Development and Industrial Pharmacy

Volumn 34, Issue 11, 2008, Pages 1209-1218

  Basa, Shradhanjali ^a   Muniyappan, Thilekkumar ^b   Karatgi, Pradeep ^b   Prabhu, Raghavendra ^b   Pillai, Ravi ^b  

^a ANNAMALAI UNIVERSITY   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Dissolution; Ketoconazole; Nanosuspension; Particle size; Poorly soluble drugs

Indexed keywords

KETOCONAZOLE; NANOPARTICLE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG MANUFACTURE; DRUG SOLUBILITY; IN VITRO STUDY; PARTICLE SIZE; SOLID; TABLET FORMULATION; X RAY DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 54349125120     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802005024     Document Type: Article

References (28)

1. Balimane, P. V., Han, Y. H., & Chong, S. (2006). Current industrial practices of assessin permeability and P-glycoprotein interaction. AAPS J., 8, E1-E13.
2. Byrn, S., Pfeiffer, S., Ganey, M., Hoiberg, C., & Poochikian, G. (1995). Pharmaceutical solids: A strategic approach to regulatory consideration. Pharm. Res., 12, 945-954.
3. Carlson, J. A., Mann, H. J., & Canafax, D. M. (1983). Effect of pH on disintegration and dissolution of ketoconazole tablets. Am. J. Hosp. Pharm., 40, 1334-1336.
4. Connors, R. D., & Elder, E. J. (2004). Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug. Deliv. Tech., 4(8), 78-83.
5. Esclusa-Diaz, M. T., Gayo-Otero, M., Perez-Marcos, M. B., Vila-Jato, J. L., & Torres-Labandeira, J. J. (1996). Preparation and evaluation of ketoconazole-/-cyclodextrin multicomponent complexes. Int. J. Pharm., 142, 183-187.
6. Galia, E., Nicolaides, E., Horter, D., Lobenberg, R., Reppas, C., & Dressman, J. B. (1998). Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res., 15, 698-705.
7. Hecq, J., Deleers, M., Fanara, D., Vranckx., & Amighi, K. (2005). Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm., 299, 167-177.
8. Hecq, J., Deleers, M., Fanara, D., Vranckx., Boulanger, P., Le Lamer, S., & Amighi, K. (2006). Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm., 64, 360-368.
9. Jacobs, C., Kayser, O., & Muller, R. H. (2006). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm., 196, 161-164.
10. Krause, K. P., & Muller, R. H. (2001). Production and characterization of highly concentrated nanosuspensions by high pressure homogenization. Int. J. Pharm., 214, 21-24.
11. Lee, J. (2003). Drug nano- and microparticles processed into solid dosage forms: Physical properties. J .Pharm. Sci., 92, 2057-2066.
12. Lee, J., & Cheng, Yu. (2006). Critical freezing rate in freeze drying nanocrystal dispersions. J. Control. Rel., 11, 185-192.
13. Levine, H. B. (1982). Ketoconazole in the management of fungal disease. New York: Adis Press.
14. Liversidge, E. M., Liversidge, G. G., & Cooper, E. R. (2003). Nanonizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci., 18, 113-120.
15. Liversidge, E. M., Sarpotdar, P., Bruno, J., Hajj, S., Wei, L., Peltier, N., Rake, J., Shaw, M., Pugh, S., Pollin, L., Jones, J., Corbett, T., Cooper, E., & Liversidge, G. G. (1996). Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res., 13, 272-278.
16. Liversidge, G. G., & Conzentino, P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm., 125, 309-313.
17. Liversidge, G. G., & Cundy, K. C. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Int. J. Pharm., 125, 91-97.
18. Mididoddi, P. K., & Repka, M. A. (2007). Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur. J. Pharm. Biopharm., 66, 95-105.
19. Muller, R. H., & Bohn, B. H. L. (1998). Nanosuspensions. In R. H. Muller, S. Benita, & B. Bohm (Eds.), Emulsions and nanosuspensions for the formulation of poorly soluble drugs (pp. 143-147). Stuttgart: Medpharm Scientific.
20. Muller, R. H., Jacobs, C., & Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev., 47, 3-19.
21. Nogami H., Nagai T., & Yotsuyanagi, T. (1969). Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem. Pharm. Bull., 17, 499-509.
22. Nystrom, C. (1998). Dissolution properties of soluble drugs: Theoretical background and possibilities to improve the dissolution behavior. In R. H. Muller, S. Benita, & B. Bohm (Eds.), Emulsions and nanosuspensions for the formulation of poorly soluble drugs (pp. 143-147). Stuttgart: Medpharm Scientific.
23. Peters, K., & Muller, R. H. (1996). Nanosuspensions for the oral application of poorly soluble drugs. In Proceeding European Symposium on Formulation of Poorly-available Drugs for Oral Administration (pp. 330-333). Paris: APGI.
24. Pharmaceutical Technical Bulletin. In Improved Dissolution of Cationic Drugs with Polyplasdone Super Disintegrants. www.ispcorp.com
25. Ploehn, H. J., & Russel, W. B. (1990). Interaction between colloidal particles and soluble polymers. Adv. Chem. Engg., 15, 137-228.
26. Shah, U., Vemavarapu, C., Askins, V., Lodaya, M., Elzinga, P., & Mollan, M. J., Jr. (2006). Nanoparticle formation: A modular high pressure system to enhance biopharmaceutical properties of poorly soluble drugs. Pharm. Tech. (www.pharmtech.com).
27. Van den Mooter, G., Wuyts, M., Blaton, N., Busson, R., Grobet, P., Augustijns, P., & Kinget, R. (2001). Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci., 12, 261-269.
28. Van der Meer, J. W. M., Keuning, J. J., Scheijgrond, H. W., Heykants, J., Van Cutsem, J., & Brugmans, J. (1980).The influence of gastric acidity on the bioavailability of ketoconazole. J. Antimicrob. Chemother., 6, 552-554.